Published in Calcif Tissue Int on February 19, 2002
Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist (2012) 1.50
Bisphosphonates pathway. Pharmacogenet Genomics (2011) 0.86
Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J (2010) 0.81
Genetics of the bone response to bisphosphonate treatments. Clin Cases Miner Bone Metab (2009) 0.76
Pharmacogenetics of osteoporosis. F1000 Biol Rep (2010) 0.76
Pharmacogenomics in osteoporosis: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.75
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Mineralisation defects with pamidronate therapy for Paget's disease. Lancet (1993) 2.76
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med (1998) 2.64
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Management of Paget's disease of bone. Rheumatology (Oxford) (2004) 2.60
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Guidelines on the management of Paget's disease of bone. Bone (2002) 2.34
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet (1996) 2.23
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet (1985) 2.15
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet (2000) 2.13
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol (2004) 2.09
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med (1996) 1.99
A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest (2001) 1.98
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol (1998) 1.94
Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ (1988) 1.89
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
Association of polymorphism at the type I collagen (COL1A1) locus with reduced bone mineral density, increased fracture risk, and increased collagen turnover. Arthritis Rheum (1999) 1.70
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70
Nitric oxide and bone. Immunology (2001) 1.60
Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res (1991) 1.57
Bone densitometry: current status and future prospects. Br J Radiol (1997) 1.57
Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss. Osteoporos Int (2003) 1.56
Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis (2010) 1.53
Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant (2006) 1.51
Contact quantitative ultrasound: an evaluation of precision, fracture discrimination, age-related bone loss and applicability of the WHO criteria. Osteoporos Int (1999) 1.51
Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med (2001) 1.49
1alpha-hydroxyvitamin D3 in primary hyperparathyroidism. Clin Endocrinol (Oxf) (1977) 1.48
Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int (2010) 1.48
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Br Med J (Clin Res Ed) (1986) 1.47
Individual kidney function in atherosclerotic nephropathy is not related to the presence of renal artery stenosis. Nephrol Dial Transplant (1999) 1.46
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (1984) 1.45
Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med (1988) 1.44
Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone (2003) 1.44
A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene (2000) 1.43
Occupational dose to the radiographer in dual X-ray absorptiometry: a comparison of pencil-beam and fan-beam systems. Br J Radiol (1996) 1.41
1, 2, 3, or 4 phase bone imaging--how many are necessary? Nucl Med Commun (1990) 1.39
Ablation of mediastinal parathyroid adenomas by superselective embolization of the internal mammary artery with alcohol. Clin Radiol (1993) 1.39
The role of nuclear medicine in orthopaedics. Nucl Med Commun (1994) 1.39
Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) (1986) 1.38
Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) (1984) 1.36
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis (1995) 1.34
Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology (2001) 1.32
Visual assessment of vertebral deformity by X-ray absorptiometry: a highly predictive method to exclude vertebral deformity. Osteoporos Int (2000) 1.30
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med (1978) 1.30
Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int (2000) 1.25
Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res (1998) 1.25
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med (1999) 1.24
Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med (1986) 1.20
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer (1997) 1.20
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol (2000) 1.18
Chronic low back pain: comparison of bone SPECT with radiography and CT. Radiology (1992) 1.18
Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet (1982) 1.15
A clinical profile of back pain and disability in patients with spinal osteoporosis. Bone (1994) 1.14
Vitamin D receptor polymorphism, bone mineral density, and osteoporotic vertebral fracture: studies in a UK population. Bone (1996) 1.14
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet (2001) 1.14
Analysis of IL-2, IL-4, and IFN-gamma-producing cells in situ during immune responses to protein antigens. J Immunol (1993) 1.13
Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res (1998) 1.13
Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int (2012) 1.13
Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol (1993) 1.13
Technical principles of dual energy x-ray absorptiometry. Semin Nucl Med (1997) 1.12
The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med (2001) 1.12
16-detector multislice CT: dosimetry estimation by TLD measurement compared with Monte Carlo simulation. Br J Radiol (2004) 1.11
Bone mineral measurements in clinical practice. Br J Hosp Med (1987) 1.11
The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol (1990) 1.10
Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med (1997) 1.10
Management of male osteoporosis: report of the UK Consensus Group. QJM (1998) 1.10
The role of positron emission tomography in the management of bone metastases. Cancer (2000) 1.10
The value of SPECT scans in identifying back pain likely to benefit from facet joint injection. Br J Rheumatol (1996) 1.09
Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism. J Immunol (1997) 1.09
Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res (2001) 1.08
Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone (1997) 1.08
Nitric oxide response to shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent. Biochem Biophys Res Commun (1998) 1.08
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet (1982) 1.08
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet (2005) 1.08
Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia (1998) 1.08
Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum (2001) 1.07
Reappraisal of the baseline bone scan in breast cancer. J Nucl Med (1988) 1.07
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int (2003) 1.07
A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res (2000) 1.07
Biochemical prediction of response of bone metastases to treatment. Br J Cancer (1988) 1.07
Inheritance of isozyme variation and heterozygosity in Pinus ponderosa. Biochem Genet (1979) 1.06
Oral surgery: ARONJ masterclass. Br Dent J (2014) 1.06
Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics (1989) 1.06
Morphometric X-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res (2000) 1.06
Estimation of skeletal involvement in primary hyperparathyroidism. Use of 24-hour whole-body retention of technetium-99m diphosphonate. Ann Intern Med (1980) 1.05